Bio-Path’s Liposomal Grb-2 Treats Blood Cancers
Just yesterday, at the 53rd Annual Meeting of the American Society of Hematology (ASH) in sunny San Diego, Bio-Path Holdings, Inc announced their results from Cohort 1 of the Phase I cancer clinical trial of its lead product candidate, BP-100-1.01 (Liposomal Grb-2). This new drug is a systemic liposomal antisense treatment for blood cancers (say that three times fast!).
The goal is to help counter the effects of chronic myelogenous leukemia (CML), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and acute lymphoblastic leukemia (ALL). There are a plethora of cancer blogs that cover these individual cancer types should you want to learn more!
This phase I research trial is being conducted over at The University of Texas MD Anderson Cancer Center, one of the most notable facilities in the country! What they are finding is that the drug is being tolerated pretty well, and has no reported treatment-related adverse events reported. What’s promising, is that they are starting to see some anti-leukemia activity at a low starting dosages.
This particular research study is continuing to obtain more patients, and Cohort 2 is now open! Referencing the early results of the study, Dr. Cortes of the MD Anderson Cancer Center stated that “BP-100-1.01 has a novel mechanism of action with potential to become an important therapy for patients with CML and other leukemias. The early data, with some suggestions of activity at very low doses, are very encouraging.”
You can also check out some of the other clinical trials in Texas here!
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company focused on developing therapeutic products utilizing its proprietary liposomal delivery technology designed to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path’s lead product candidate, Liposomal Grb-2, is in a Phase I study for blood cancers.
Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors, and its third candidate is a liposomal siRNA cancer drug that is in the final pre-clinical development stage. These product candidates and the delivery technology have been licensed from The University of Texas MD Anderson Cancer Center.
Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Bio-Path’s ability to raise needed additional capital on a timely basis in order for it to continue its operations, have success in the clinical development of its technologies, the timing of enrollment and release of data in such clinical studies and the accuracy of such data, limited patient populations of early stage clinical studies and the possibility that results from later stage clinical trials with much larger patient populations may not be consistent with earlier stage clinical trials, and such other risks which are identified in the Company’s most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Bio-Path Holdings or at www.sec.gov . Bio-Path disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information, please visit the Company’s website at http://www.biopathholdings.com